Inventor · disambiguated record
Sean Colm Turner
Also filed as: TURNER SEAN · TURNER SEAN C · TURNER SEAN COLM
51 granted patents·23 pending applications·346 citations·filing 1998–2024
98Inventor score
Top patents by PatentIndex Score
74 records- 0193US9273068B2Substituted isoquinolines and phthalazines as inhibitors of phosphodiesterase type 10AABBOTT GMBH & CO KG·Filed 2012·Granted Mar 1, 2016·25 cites·44 claims
- 0292US8648069B25-substituted indazoles as kinase inhibitorsAKRITOPOULOU-ZANZE IRINI·Filed 2008·Granted Feb 11, 2014·44 cites·7 claims
- 0391US7348343B2Amides useful for treating painABBOTT LAB·Filed 2006·Granted Mar 25, 2008·8 cites·11 claims
- 0489US7129235B2Amides useful for treating painABBOTT LAB·Filed 2004·Granted Oct 31, 2006·32 cites·33 claims
- 0589US6410628B1Photoactivatable nitrogen-containing bases based on alpha-amino ketonesCIBA SC HOLDING AG·Filed 2001·Granted Jun 25, 2002·21 cites·12 claims
- 0688US9090592B2Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitorsTURNER SEAN COLM·Filed 2011·Granted Jul 28, 2015·6 cites·29 claims
- 0788US8440694B2Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin-5-HT6 receptorTURNER SEAN COLM·Filed 2012·Granted May 14, 2013·12 cites·13 claims
- 0888US8318793B2Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitorsTURNER SEAN COLM·Filed 2010·Granted Nov 27, 2012·17 cites·19 claims
- 0986US9266855B2Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitorsTURNER SEAN COLM·Filed 2011·Granted Feb 23, 2016·11 cites·22 claims
- 1085US6933311B2Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptorABBOTT LAB·Filed 2003·Granted Aug 23, 2005·24 cites·23 claims
- 1184US9163007B25-substituted indazoles as kinase inhibitorsABBVIE INC·Filed 2013·Granted Oct 20, 2015·8 cites·6 claims
- 1282US7074805B2Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptorABBOTT LAB·Filed 2003·Granted Jul 11, 2006·10 cites·69 claims
- 1382US6277986B1Photoactivatable nitrogen-containing bases based on α-amino ketonesCIBA SC HOLDING AG·Filed 1998·Granted Aug 21, 2001·23 cites·7 claims
- 1481US7875627B2Thienopyridyl compounds that inhibit vanilloid receptor subtype 1 (VR1) and uses thereofABBOTT LAB·Filed 2005·Granted Jan 25, 2011·4 cites·19 claims
- 1580US10556907B2Fused heterocyclic compounds as S1P modulatorsABBVIE INC·Filed 2016·Granted Feb 11, 2020·5 cites·12 claims
- 1680US7790727B2Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptorABBOTT GMBH & CO KG·Filed 2008·Granted Sep 7, 2010·4 cites·31 claims
- 1780US7335678B2Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1(VR1) receptorABBOTT LAB·Filed 2004·Granted Feb 26, 2008·8 cites·12 claims
- 1876US7851463B2Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptorABBOTT GMBH & CO KG·Filed 2005·Granted Dec 14, 2010·2 cites·21 claims
- 1976US7320979B2N-[(piperazinyl)hetaryl]arylsulfonamide compoundsABBOTT GMBH & CO KG·Filed 2004·Granted Jan 22, 2008·7 cites·22 claims
- 2075US9790203B2Inhibitor compounds of phosphodiesterase type 10AABBVIE DEUTSCHLAND·Filed 2013·Granted Oct 17, 2017·2 cites·26 claims
- 2174US8242102B2Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptorTURNER SEAN COLM·Filed 2008·Granted Aug 14, 2012·2 cites·23 claims
- 2273US8969552B2Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptorDRESCHER KARLA·Filed 2005·Granted Mar 3, 2015·2 cites·25 claims
- 2371US8455648B21-(7-(hexahydropyrrolo [3,4-c] pyrrol-2 (1H)-yl) quinolin-4-yl) -3- (pyrazin-2-yl) urea derivatives and related compounds as glycogen synthase kinase 3 (GSK-3)TURNER SEAN COLM·Filed 2009·Granted Jun 4, 2013·1 cites·19 claims
- 2471US8232426B2Aminoethylaromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptorDRESCHER KARLA·Filed 2005·Granted Jul 31, 2012·1 cites·19 claims
- 2571US2025296917A1Spiro-cyclic amine derivatives as s1p modulatorsABBVIE DEUTSCHLAND·Filed 2024·Application pending·0 cites
- 2668US8507469B2Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptorSCHULTZ THOMAS·Filed 2008·Granted Aug 13, 2013·2 cites·44 claims
- 2767US8877794B2Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapyPOHLKI FRAUKE·Filed 2011·Granted Nov 4, 2014·1 cites·18 claims
- 2867US6087070APhotoactivatable nitrogen-containing bases based on α-amino alkenesCIBA SC HOLDING AG·Filed 1998·Granted Jul 11, 2000·25 cites·21 claims
- 2965US8101754B2Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptorUNGER LILIANE·Filed 2005·Granted Jan 24, 2012·1 cites·21 claims
- 3065US6551761B1Photoactivatable nitrogen-containing bases based on α-ammonium ketones, iminium ketones or amidinium ketones and aryl boratesCIBA SPECIALTY CHEMICAL CORP·Filed 2000·Granted Apr 22, 2003·22 cites·18 claims
- 3165US2008153809A1Novel amides useful for treating painABBOTT LAB·Filed 2008·Application pending·0 cites
- 3264US8247413B2Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptorLEE CHIH-HUNG·Filed 2008·Granted Aug 21, 2012·0 cites·10 claims
- 3362US2022169620A1Spiro-cyclic amine derivatives as s1p modulatorsABBVIE DEUTSCHLAND·Filed 2021·Application pending·0 cites
- 3461US2010210664A1Benzenesulfonamide compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptorTURNER SEAN COLM·Filed 2008·Application pending·0 cites
- 3561US2015175570A1Benzenesulfonamide compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptorABBVIE DEUTSCHLAND·Filed 2014·Application pending·0 cites
- 3659US2014200224A1Benzenesulfonamide compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptorABBVIE DEUTSCHLAND·Filed 2013·Application pending·0 cites
- 3758US8293913B2Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin-5-HT6 receptorTURNER SEAN COLM·Filed 2008·Granted Oct 23, 2012·0 cites·13 claims
- 3855US6489374B1Photoactivatable bases containing nitrogenCIBA SC HOLDING AG·Filed 1999·Granted Dec 3, 2002·16 cites·17 claims
- 3955US2007054918A1N-[(piperazinyl)hetary]arylsulfonamide compounds with affinity for the dopamine d3 receptorBRAJE WILFRIED·Filed 2004·Application pending·0 cites
- 4054US9856234B2Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitorsABBVIE INC·Filed 2014·Granted Jan 2, 2018·0 cites·13 claims
- 4154US9238619B2Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapyABBVIE DEUTSCHLAND·Filed 2014·Granted Jan 19, 2016·0 cites·26 claims
- 4254US2013116241A1Novel inhibitor compounds of phosphodiesterase type 10aABBOTT GMBH & CO KG·Filed 2012·Application pending·0 cites
- 4353US2011319421A1Benzenesulfonamide compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptorTURNER SEAN COLM·Filed 2011·Application pending·0 cites
- 4453US2018346484A1Modulators of 5-ht receptors and methods of use thereofABBVIE DEUTSCHLAND·Filed 2018·Application pending·0 cites
- 4552US8492540B21,2,4,-triazin-3,5-dione compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptorBRAJE WILFRIED·Filed 2008·Granted Jul 23, 2013·0 cites·20 claims
- 4652US8476275B2N-[piperazinyl hetaryl]arylsufonamide compounds with affinity for the dopamine D3 receptorBRAJE WILFRIED·Filed 2011·Granted Jul 2, 2013·0 cites·3 claims
- 4751US9540370B2Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitorsABBVIE DEUTSCHLAND·Filed 2015·Granted Jan 10, 2017·0 cites·28 claims
- 4850US8642598B2Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitorsTURNER SEAN C·Filed 2007·Granted Feb 4, 2014·0 cites·18 claims
- 4949US9657034B2Substituted furo[3,2-c]pyridines, thieno[3,2-c]pyridines, thieno[2,3-d]pyridazines and pyrido[3,4-d]pyridazines as phosphodiesterase type 10A inhibitorsABBVIE DEUTSCHLAND·Filed 2016·Granted May 23, 2017·0 cites·61 claims
- 5049US2018030033A1Novel inhibitor compounds of phosphodiesterase type 10aABBVIE INC·Filed 2017·Application pending·0 cites
Showing the top 50 of 74 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →